granisetron


Also found in: Wikipedia.

granisetron

 [gră-nis´ĕ-tron]
an antiemetic used in conjunction with cancer chemotherapy or radiotherapy; administered orally or intravenously as the hydrochloride salt.

granisetron

Kytril® Oncology A 5-HT3–serotonin receptor antagonist antiemetic used for Pts receiving chemotherapy–eg, cisplatin, cyclophosphamide Adverse effects Headache–35%, constipation–30%, asthenia, somnolence, diarrhea

Granisetron

A serotonin antagonist drug that blocks the nausea receptors in the small intestine and is used to control sickness and vomiting after surgery and in patients on anticancer chemotherapy. It can be used in children. A brand name is Kytril.
References in periodicals archive ?
Contract notice: conclusion of non-exclusive discount agreements pursuant to section 130a (8) sgb v on medicines containing the active substance granisetron, only ampoules and film-coated tablets as part of a so-called open-house model.
[10] In a study conducted by Bhatacharjee DP et al, [21] palonosetron was proved to be an effective antiemetic than granisetron for prevention of postoperative nausea and vomiting.
Biotechnology company Heron Therapeutics (NasdaqCM:HRTX) announced on Friday that its New Drug Application (NDA) resubmission for SUSTOL (granisetron) Injection, extended release has been accepted for review.
All patients received antiemetic prophylaxis with dexamethasone, granisetron and/or droperidol using monotherapy in nine patients (22%), dual therapy in 30 patients (73%) and three agents in two patients (5%).
Contract notice: open house drug discount granisetron, atc code a04aa02
Following the re submission of SUSTOL (granisetron) Injection extended release, the company expects expects confirmation of acceptance from the US FDA, a Prescription Drug User Fee Act (PDUFA) goal date within the next few weeks as well as a six-month review by the US FDA.
Granisetron reduces postoperative nausea and vomiting throughout menstrual cycle.
Granisetron hydrochloride Bedford Laboratories 1/20/2006
[3,4] Granisetron was introduced in 1993 and was initially used only for prevention of chemotherapy-induced nausea and vomiting.
Net proceeds may be used by the company primarily for general corporate purposes, the commercial launch of SUSTOL (granisetron injection, extended release), funding its ongoing and future clinical trials, preclinical development work, other product development activities as well as general and administrative expenses.
Serotonin type 3 (5-[HT.sub.3]) receptor antagonists, such as ondansetron, granisetron and tropisetron, have been shown to reduce the incidence of PONV in children (4,6,7,12,13).